Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Rakovina Therapeutics Inc.
  6. News
  7. Summary
    RKV   CA75103L1013

RAKOVINA THERAPEUTICS INC.

(RKV)
Delayed Bourse de Toronto  -  12:40 2022-11-24 pm EST
0.1950 CAD   +30.00%
11/23Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
GL
11/23Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
AQ
11/17Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
GL
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

04/26/2022 EST

Rakovina Therapeutics Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was CAD 5.52 million. Basic loss per share from continuing operations was CAD 0.1. Diluted loss per share from continuing operations was CAD 0.1.


ę S&P Capital IQ 2022
All news about RAKOVINA THERAPEUTICS INC.
11/23Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
GL
11/23Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
AQ
11/17Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate U..
GL
11/17Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate U..
AQ
11/16Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/14Rakovina Therapeutics Says Publication Highlights Activity of Dual PARP-HDAC Inhibitor ..
MT
11/14Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functiona..
GL
11/14Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functiona..
AQ
10/31Rakovina Therapeutics Presented Preclinical Data at Molecular Targets and Cancer Therap..
MT
10/31Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AAC..
GL
More news
Financials
Sales 2021 - - -
Net income 2021 -5,52 M -4,13 M -4,13 M
Net cash 2021 2,81 M 2,10 M 2,10 M
P/E ratio 2021 -2,14x
Yield 2021 -
Capitalization 13,6 M 10,2 M 10,2 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 54,8%
Chart RAKOVINA THERAPEUTICS INC.
Duration : Period :
Rakovina Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Mads Daugaard President & Chief Scientific Officer
David Hyman Chief Financial Officer & Secretary
Jeffrey A. Bacha Executive Chairman
John Langlands Chief Operating Officer
Alfredo J. de Lucrezia Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
RAKOVINA THERAPEUTICS INC.-11.36%10
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930